BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fernández MS, Marín F, Rafols C, Arribas F, Barrios V, Cosín-Sales J, Sánchez MA; the EMIR Study Investigators:. Thromboembolic and bleeding events with rivaroxaban in clinical practice in Spain: impact of inappropriate doses (the EMIR study). J Comp Eff Res 2021;10:583-93. [PMID: 33787316 DOI: 10.2217/cer-2020-0286] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Kong X, Zhu Y, Pu L, Meng S, Zhao L, Zeng W, Sun W, Wu G, Li H. Efficacy and Safety of Non-recommended Dose of New Oral Anticoagulants in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Front Cardiovasc Med 2021;8:774109. [PMID: 35004891 DOI: 10.3389/fcvm.2021.774109] [Reference Citation Analysis]
2 Escobar Cervantes C, Barrios Alonso V. Direct oral anticoagulants today. Med Clin (Barc) 2021;157:238-40. [PMID: 34353625 DOI: 10.1016/j.medcli.2021.07.001] [Reference Citation Analysis]
3 Wu X, Hu L, Liu J, Gu Q. Off-Label Underdosing or Overdosing of Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation: A Meta-Analysis. Front Cardiovasc Med 2021;8:724301. [PMID: 34568462 DOI: 10.3389/fcvm.2021.724301] [Reference Citation Analysis]